The pharmacological and clinical profile of Klimonorm (R). An overview

This paper gives a short overview of the pharmacological and clinical profi le of the sequential oral estrogen-progestogen hormone replacement drug Kli monorm (R), which contains estradiol valerate and levonorgestrel. The clini cal effectiveness of Klimonorm (R) has been shown by its alleviation of cla ssic vasomotor menopausal complaints, such as hot flushes and sweating, as well as the alleviation of some psychological symptoms, prevention of postm enopausal osteoporosis, counteraction of the symptoms and signs of urogenit al atrophy, and favorable effects on lipid metabolism. Therapy with Klimono rm (R) has also resulted in stabilization of the cycle length, with a high reproducibility of cycle appearance and duration (usually 3-4 days). Cycles with regular withdrawal bleeding were restored in more than 90% of the wom en studied. The thickness of the endometrium, measured sonographically, did not change significantly during 3 years of therapy with Klimonorm (R). The antioxidative action of estradiol valerate was not modified in the presenc e of levonorgestrel. There were no clinically significant changes in body w eight, blood pressure, hematological tests or parameters of clinical chemis try during Klimonorm (R) therapy. (C) 2001 Prous Science. All rights reserv ed.